BOEHRINGER-INGELHEIM
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.
Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.
“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”
Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.
Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD® , a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD® , which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.
For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005402/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting forbedrer sine organisatoriske udviklingskapaciteter med Omni HR Consulting1.8.2025 19:22:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for menneskelige ressourcer gennem en samarbejdsaftale med Omni HR Consulting, et sydafrikansk konsulentfirma med speciale i løsninger til forretnings- og personaleudvikling. Omni HR Consulting tilbyder en komplet pakke af tjenester, der omfatter organisationsudvikling, præstationsrådgivning, akkrediteret uddannelse, kompetenceudvikling og ledelsesprogrammer gennem sit Business and Leadership Academy. Virksomheden samarbejder med kunderne om at designe og implementere løsninger, der retter sig mod medarbejdernes kompetencer, optimering af resultater og strategisk tilpasning og understøttes af en konsekvent tilgang til projektledelse og overholdelse af sydafrikanske kvalitetsstandarder. "Hos Omni tror vi på, at effektiv udvikling starter med forståelse af konteksten," siger administrerende direktør Lize Moldenhauer. "Vi arbejder tæt sammen med vores kunder for at udvikle skræddersyede løsninger, der skaber målbare fremskridt – hvad ente
DevvStream Deploys Crypto Treasury with Initial Bitcoin and Solana Purchases; Intends to Expand Credit Facility to $300M1.8.2025 16:00:00 CEST | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced the initial deployment of its crypto treasury strategy with purchases of Bitcoin ($BTC) and Solana ($SOL), funded by a portion of the first (US)$10 million tranche of its (US)$300 million senior secured convertible notes facility with Helena Global Investment Opportunities 1 Ltd. These acquisitions represent the operational launch of DevvStream’s digital treasury strategy, designed to combine institutional-grade liquidity with blockchain infrastructure. The Company believes Bitcoin provides a liquid, non-correlated store of value and that Solana’s high-throughput network supports the Company’s long-term objectives in, and the industry’s move towards, sustainability-linked tokenization. In parallel, DevvStream announced its intention to increase its existing Equity Line of Credit (ELOC) to (US)$30
BEYOND Launches PASSO, a Sculptural Icon on Palm Jumeirah1.8.2025 15:17:00 CEST | Press release
BEYOND Developments, the forward-thinking real estate brand shaping lifestyle destinations by the sea, has unveiled PASSO, a sculptural waterfront development located on the prestigious West Crescent of Palm Jumeirah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250801880717/en/ PASSO by BEYOND, a Sculptural Icon on Palm Jumeirah. (Photo: AETOSWire) As BEYOND’s first flagship beyond its masterplan in Dubai Maritime City, PASSO marks a defining milestone in the company’s strategic growth to one of the world’s most iconic and desirable destinations. The project launched with a spectacular Palm Jumeirah event featuring Dubai’s first-ever “screens in the sky” show, a 13-minute performance with over 4,000 drones blending immersive visuals and live stage action. Comprising two sculptural towers, Avita and Bella, PASSO offers 625 residences in a refined mix of layouts. From one-bedroom retreats and two-to-four-bedroom-plus lifest
LevelBlue Completes Acquisition of Aon’s Cybersecurity and IP Litigation Consulting Groups1.8.2025 14:00:00 CEST | Press release
Strategic deal enhances LevelBlue's cybersecurity offerings, solidifying its position as the world’s largest leading independent, pure-play MSSP LevelBlue, a global leader in cloud-based, AI-driven managed security services, today announced the completion of its acquisition of Aon’s (NYSE: AON) Cybersecurity and Intellectual Property (IP) Litigation consulting groups, including the renowned cybersecurity firm, Stroz Friedberg, and Elysium Digital. With this completion the consulting group will operate as Stroz Friedberg, a LevelBlue company. This strategic acquisition adds elite cyber and high-tech IP litigation consulting expertise to the LevelBlue portfolio, which includes a globally recognized platform of approximately 300 technology professionals with deep relationships across Fortune 500 companies, 80 percent of the Am Law 100, and most of the UK’s top 20 law firms. As a result, LevelBlue will significantly fortify its incident response and advisory capabilities, while expanding i
SBC Medical to Announce Q2 2025 Financial Results and Hold Conference Call on August 13, 20251.8.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global franchise and provider of services for aesthetic clinics, today announced that it will report its Q2 2025 financial results on Wednesday, August 13, 2025, before the U.S. market opens. The Company will hold a conference call on Wednesday, August 13, 2025 at 8:30 am Eastern Time (or Wednesday, August 13, 2025 at 9:30 pm Japan Time) to discuss the financial results and take questions live. Please register in advance of the conference using the link provided below. https://edge.media-server.com/mmc/p/ukc9sp9j It will automatically direct you to the registration page of “SBC Q2 2025 Financial Results Presentation.” Please follow the steps to enter your registration details, then click “Submit.” Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom